PL392790A1 - Związki pirazolo [3, 4-b] pirydynowe i ich zastosowanie jako inhibitorów fosfodiesterazy - Google Patents

Związki pirazolo [3, 4-b] pirydynowe i ich zastosowanie jako inhibitorów fosfodiesterazy

Info

Publication number
PL392790A1
PL392790A1 PL392790A PL39279003A PL392790A1 PL 392790 A1 PL392790 A1 PL 392790A1 PL 392790 A PL392790 A PL 392790A PL 39279003 A PL39279003 A PL 39279003A PL 392790 A1 PL392790 A1 PL 392790A1
Authority
PL
Poland
Prior art keywords
pyrazole
phosphodiesterase inhibitors
pyridine compounds
pyridine
compounds
Prior art date
Application number
PL392790A
Other languages
English (en)
Polish (pl)
Inventor
David George Allen
Diane Mary Coe
Caroline Mary Cook
Anthony William James Cooper
Michael Dennis Dowle
Christopher David Edlin
Julie Nicole Hamblin
Martin Redpath Johnson
Paul Spencer Jones
Mika Kristian Lindvall
Charlotte Jane Mitchell
Alison Judith Redgrave
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0230165A external-priority patent/GB0230165D0/en
Priority claimed from GB0307998A external-priority patent/GB0307998D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of PL392790A1 publication Critical patent/PL392790A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL392790A 2002-12-23 2003-12-19 Związki pirazolo [3, 4-b] pirydynowe i ich zastosowanie jako inhibitorów fosfodiesterazy PL392790A1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0230045.7A GB0230045D0 (en) 2002-12-23 2002-12-23 Compounds
GB0230165A GB0230165D0 (en) 2002-12-24 2002-12-24 Compounds
GB0307998A GB0307998D0 (en) 2003-04-07 2003-04-07 Compounds

Publications (1)

Publication Number Publication Date
PL392790A1 true PL392790A1 (pl) 2011-01-03

Family

ID=32685762

Family Applications (2)

Application Number Title Priority Date Filing Date
PL377880A PL377880A1 (pl) 2002-12-23 2003-12-19 Związki pirazolo [3,4-b] pirydynowe i ich zastosowanie jako inhibitorów fosfodiesterazy
PL392790A PL392790A1 (pl) 2002-12-23 2003-12-19 Związki pirazolo [3, 4-b] pirydynowe i ich zastosowanie jako inhibitorów fosfodiesterazy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL377880A PL377880A1 (pl) 2002-12-23 2003-12-19 Związki pirazolo [3,4-b] pirydynowe i ich zastosowanie jako inhibitorów fosfodiesterazy

Country Status (28)

Country Link
US (1) US7528148B2 (enExample)
EP (1) EP1581532B1 (enExample)
JP (1) JP4872068B2 (enExample)
KR (1) KR101088848B1 (enExample)
CN (1) CN1751042B (enExample)
AR (1) AR043683A1 (enExample)
AT (1) ATE466012T1 (enExample)
AU (2) AU2003293999B2 (enExample)
BR (1) BR0317645A (enExample)
CA (1) CA2511340C (enExample)
CO (1) CO5690642A2 (enExample)
CY (1) CY1110676T1 (enExample)
DE (1) DE60332396D1 (enExample)
DK (1) DK1581532T3 (enExample)
ES (1) ES2345385T3 (enExample)
GB (1) GB0230045D0 (enExample)
IL (1) IL169335A0 (enExample)
IS (1) IS2795B (enExample)
MA (1) MA27615A1 (enExample)
MX (1) MXPA05006923A (enExample)
NO (1) NO332354B1 (enExample)
NZ (2) NZ540923A (enExample)
PL (2) PL377880A1 (enExample)
PT (1) PT1581532E (enExample)
SI (1) SI1581532T1 (enExample)
TW (2) TW201004956A (enExample)
WO (1) WO2004056823A1 (enExample)
ZA (1) ZA200605901B (enExample)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
DE60329193D1 (de) * 2002-09-16 2009-10-22 Glaxo Group Ltd Pyrazolo(3,4-b)pyridinverbindungen und ihre verwendung als phosphodiesterasinhibitoren
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
JP2007514704A (ja) * 2003-12-19 2007-06-07 グラクソ　グループ　リミテッド ピラゾロ［３，４−ｂ］ピリジン化合物およびホスホジエステラーゼ阻害剤としてのその使用
EP1735314A1 (en) * 2004-03-16 2006-12-27 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
GB0405933D0 (en) * 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
ATE517908T1 (de) 2005-01-10 2011-08-15 Glaxo Group Ltd Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
KR20140022114A (ko) 2005-06-06 2014-02-21 다케다 야쿠힌 고교 가부시키가이샤 유기 화합물
WO2007000043A2 (en) * 2005-06-27 2007-01-04 Ambrilia Biopharma Inc. Pyrazolo[3,4-b]pyridin-2-yl]-benzoic acid derivatives as hiv integrase inhibitors
US20090325924A1 (en) * 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
WO2007003961A2 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
WO2007031977A2 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors
EP1940836A1 (en) * 2005-09-29 2008-07-09 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
PE20071068A1 (es) 2005-12-20 2007-12-13 Glaxo Group Ltd Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
JP2009529047A (ja) * 2006-03-07 2009-08-13 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環系ピラゾール化合物およびその使用
TW200811111A (en) 2006-04-20 2008-03-01 Glaxo Group Ltd Novel compounds
EP2032585B1 (de) * 2006-05-24 2014-07-23 Boehringer Ingelheim International GmbH Substituierte pteridine als therapeutika
WO2007143705A2 (en) 2006-06-06 2007-12-13 Intra-Cellular Therapies, Inc. Organic compounds
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
AR061571A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto sal del acido toluenosulfonico de 4-{[6-cloro-3-({[(2- cloro-3-fluorofenil) amino]carbonil} amino)- 2- hidroxifenil]sulfonil] -1- piperazinacarbxilato de 1.1-dimetiletilo, composicion farmaceutica que lo comprende su uso para la fabricacion de un medicamento combinacion farmaceutica con un
GB0614570D0 (en) * 2006-07-21 2006-08-30 Glaxo Group Ltd Compounds
WO2008015416A1 (en) 2006-08-01 2008-02-07 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
US8492378B2 (en) * 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
ATE545417T1 (de) * 2007-03-14 2012-03-15 Ranbaxy Lab Ltd Pyrazoloä3,4-büpyridin-derivate als phosphodiesterasehemmer
WO2008111009A1 (en) * 2007-03-14 2008-09-18 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
EP2197873B1 (en) 2007-09-20 2014-07-16 Irm Llc Compounds and compositions as modulators of gpr119 activity
US8080546B2 (en) 2007-10-26 2011-12-20 Amgen Inc. Pyrazolo-pyridinone derivatives and methods of use
CN101969774A (zh) * 2007-12-06 2011-02-09 细胞内治疗公司 有机化合物
WO2009100170A1 (en) * 2008-02-06 2009-08-13 Glaxo Group Limited Dual pharmacophores - pde4-muscarinic antagonistics
TW201000476A (en) 2008-02-06 2010-01-01 Glaxo Group Ltd Dual pharmacophores-PDE4-muscarinic antagonistics
AR070563A1 (es) * 2008-02-06 2010-04-21 Glaxo Group Ltd Compuesto de un biciclo condensado pirazol-piridin-amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de enfermedades respiratorias.
TW200946526A (en) * 2008-02-06 2009-11-16 Glaxo Group Ltd Dual pharmacophores-PDE4-muscarinic antagonistics
EP2249646A4 (en) * 2008-02-06 2013-09-25 Glaxo Group Ltd PDE4 muscarinic Antagonist-DOPPELPHARMACOPHOREN
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
SG190667A1 (en) 2008-05-23 2013-06-28 Panmira Pharmaceuticals Llc 5-lipoxygenase-activating protein inhibitor
ES2566339T3 (es) 2008-06-05 2016-04-12 Glaxo Group Limited Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
KR101621444B1 (ko) * 2008-07-02 2016-05-19 (주)아모레퍼시픽 바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염, 및 이를 포함하는 약학 조성물
EP2346867A1 (en) * 2008-09-19 2011-07-27 Ranbaxy Laboratories Limited Phosphodiestarase inhibitors
US8697710B2 (en) 2008-12-06 2014-04-15 Intra-Cellular Therapies, Inc. Optionally substituted 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo [3,4-d]pyrimidin-6(7H)-ones
JP5989993B2 (ja) 2008-12-06 2016-09-07 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
CA2740385A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
EA201170772A1 (ru) 2008-12-06 2012-03-30 Интра-Селлулар Терапиз, Инк. Органические соединения
KR20110103949A (ko) * 2008-12-06 2011-09-21 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CN102231953A (zh) 2008-12-06 2011-11-02 细胞内治疗公司 有机化合物
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
AU2009340893B2 (en) 2009-02-24 2015-11-12 Boydel Investments Group Inc. Wastewater treatment apparatus and method
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
EP2406249A1 (en) 2009-03-10 2012-01-18 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
EP2408769A1 (en) 2009-03-17 2012-01-25 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
KR20110137799A (ko) 2009-03-19 2011-12-23 머크 샤프 앤드 돔 코포레이션 짧은 간섭 핵산 (ｓｉＮＡ) 서열 목록을 사용한 ＢＴＢ 및 ＣＮＣ 상동체 1, 염기성 류신 지퍼 전사 인자 1 (ＢＡＣＨ1) 유전자 발현의 ＲＮＡ 간섭 매개 억제
EP2408916A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120035247A1 (en) 2009-03-19 2012-02-09 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EP2408915A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
JP2012521764A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた胸腺間質性リンパ球新生因子（ＴＳＬＰ）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2411019A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2010229847A1 (en) 2009-03-27 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of the intercellular adhesion molecule 1 (ICAM-1)gene expression using short interfering nucleic acid (siNA)
US20120010272A1 (en) 2009-03-27 2012-01-12 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010122088A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
TW201103892A (en) 2009-04-24 2011-02-01 Glaxo Group Ltd Compounds
ES2644724T3 (es) 2009-04-30 2017-11-30 Glaxo Group Limited Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
EP2507226A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
US20120238571A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Indazole derivatives as pi 3-kinase
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
CA2784710A1 (en) * 2009-12-15 2011-06-23 Shionogi & Co., Ltd. Oxadiazole derivative having endothelial lipase inhibitory activity
WO2011107394A1 (en) 2010-03-01 2011-09-09 Glaxo Group Limited Treatment of anxiety disorders
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
WO2011153138A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
JP5876051B2 (ja) 2010-09-08 2016-03-02 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
HUE026059T2 (en) 2010-09-08 2016-05-30 Glaxosmithkline Ip Dev Ltd N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazol-6-yl ] Polymorphs and salts of 2 - (methyloxy) -3-pyridinyl] methanesulfonamide
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
EP2630127A1 (en) 2010-10-21 2013-08-28 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
JP5795643B2 (ja) 2010-10-21 2015-10-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
WO2012123312A1 (en) 2011-03-11 2012-09-20 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2013117693A1 (en) 2012-02-10 2013-08-15 Glaxosmithkline Intellectual Property Development Limited Pde4 inhibitor for treating huntington's disease
SG11201406552UA (en) 2012-04-25 2014-11-27 Takeda Pharmaceutical Nitrogenated heterocyclic compound
US9527841B2 (en) 2012-07-13 2016-12-27 Takeda Pharmaceutical Company Limited Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
EP2956141A4 (en) 2013-02-17 2016-10-26 Intra Cellular Therapies Inc NEW USES
JP6280912B2 (ja) 2013-03-14 2018-02-14 武田薬品工業株式会社 複素環化合物
US9545406B2 (en) 2013-03-15 2017-01-17 Intra-Cellular Therapies, Inc. Method of treating a CNS injury with a PDE1 inhibitor
MX378194B (es) 2013-03-15 2025-03-10 Intra Cellular Therapies Inc Compuestos organicos.
WO2015002231A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
EP3018123B1 (en) 2013-07-03 2023-05-10 Takeda Pharmaceutical Company Limited Amide compound
WO2015012328A1 (ja) 2013-07-24 2015-01-29 武田薬品工業株式会社 複素環化合物
AU2014336250A1 (en) 2013-10-17 2016-04-14 Glaxosmithkline Intellectual Property Development Limited PI3K inhibitor for treatment of respiratory disease
US20160263109A1 (en) 2013-10-17 2016-09-15 Glaxosmithkline Intellectual Property Development Limited P13k inhibitor for treatment of respiratory disease
JP2017515840A (ja) 2014-05-12 2017-06-15 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 感染症を治療するためのダニリキシンを含む医薬組成物
US9884872B2 (en) 2014-06-20 2018-02-06 Intra-Cellular Therapies, Inc. Organic compounds
JP6591530B2 (ja) 2014-08-07 2019-10-16 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
KR102332957B1 (ko) 2014-09-17 2021-11-29 인트라-셀룰라 써래피스, 인코퍼레이티드. 화합물 및 방법
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
ES2906107T3 (es) 2016-09-12 2022-04-13 Intra Cellular Therapies Inc Usos novedosos
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
KR102794907B1 (ko) * 2017-11-27 2025-04-14 다트 뉴로사이언스, 엘엘씨 Pde1 억제제로서의 치환된 푸라노피리미딘 화합물
MX2020006174A (es) 2017-12-14 2022-09-27 H Lundbeck As Tratamientos de combinación que comprenden la administración de 1h-pirazol[4,3-b]piridinas.
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
CN111511742B (zh) 2017-12-20 2023-10-27 H.隆德贝克有限公司 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶
US10766893B2 (en) * 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
AU2019206438B2 (en) * 2018-01-12 2023-12-07 Aurigene Oncology Limited 1,2,4-oxadiazole compounds as inhibitors of CD47 signalling pathways
US11839614B2 (en) 2018-01-31 2023-12-12 Intra-Cellular Therapies, Inc. Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
JP7612672B2 (ja) 2019-09-03 2025-01-14 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規化合物
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease
WO2023049199A1 (en) * 2021-09-24 2023-03-30 Zeno Management, Inc. Azole compounds
WO2024143336A1 (ja) * 2022-12-28 2024-07-04 日本曹達株式会社 ヒドラジド化合物および農園芸用殺菌剤

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787249A (fr) 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
US3833594A (en) 1971-08-05 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxylic acids and esters
US3925388A (en) 1971-08-05 1975-12-09 Squibb & Sons Inc 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters
US3856799A (en) 1971-08-05 1974-12-24 Squibb & Sons Inc Intermediates for production of amino derivatives of pyrazolopyridine carboxylic acids and esters
CA1003419A (en) 1971-11-23 1977-01-11 Theodor Denzel Process for the production of pyrazolo (3,4-b) pyridines
US3979399A (en) 1972-11-15 1976-09-07 E. R. Squibb & Sons, Inc. Amino derivatives of pyrazolopyridine carboxamides
US3840546A (en) 1972-11-15 1974-10-08 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxamides
US3833598A (en) 1972-12-29 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters
US4115394A (en) 1974-05-06 1978-09-19 E. R. Squibb & Sons, Inc. Amino derivatives of 6-phenylpyrazolo[3,4-b]pyridines
US4364948A (en) 1981-09-28 1982-12-21 Ici Americas Inc. Pyrazolo[3,4-b]pyridine compounds
GB8425104D0 (en) 1984-10-04 1984-11-07 Ici America Inc Amide derivatives
PL181895B1 (pl) * 1994-06-16 2001-10-31 Pfizer Nowe pirazolo-i pirolopirydyny _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ PL PL PL PL
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
CA2299502A1 (en) 1997-08-06 1999-02-18 Basf Aktiengesellschaft Substituted herbicide tetrazolinonecarboxylic acid amides
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
OA12050A (en) 1999-09-30 2006-05-02 Neurogen Corp Certain alkylene diamine-substituted heterocycles.
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
JP2002020386A (ja) 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
US6670364B2 (en) 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
US7342021B2 (en) 2001-02-08 2008-03-11 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
TWI236474B (en) 2001-04-03 2005-07-21 Telik Inc Antagonists of MCP-1 function and methods of use thereof
FR2828693B1 (fr) 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
US20050043319A1 (en) 2001-08-14 2005-02-24 Exonhit Therapeutics Sa Molecular target of neurotoxicity
DE60329193D1 (de) 2002-09-16 2009-10-22 Glaxo Group Ltd Pyrazolo(3,4-b)pyridinverbindungen und ihre verwendung als phosphodiesterasinhibitoren
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
JP2007514704A (ja) 2003-12-19 2007-06-07 グラクソ　グループ　リミテッド ピラゾロ［３，４−ｂ］ピリジン化合物およびホスホジエステラーゼ阻害剤としてのその使用
EP1735314A1 (en) 2004-03-16 2006-12-27 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
GB0405937D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
DE60332396D1 (de) 2010-06-10
JP2006513258A (ja) 2006-04-20
EP1581532B1 (en) 2010-04-28
BR0317645A (pt) 2005-12-06
GB0230045D0 (en) 2003-01-29
ZA200605901B (en) 2007-12-27
CA2511340A1 (en) 2004-07-08
US20060252790A1 (en) 2006-11-09
ATE466012T1 (de) 2010-05-15
ES2345385T3 (es) 2010-09-22
AU2010202035A1 (en) 2010-06-10
MA27615A1 (fr) 2005-11-01
AR043683A1 (es) 2005-08-10
SI1581532T1 (sl) 2010-08-31
TW200500364A (en) 2005-01-01
NZ570085A (en) 2009-02-28
CA2511340C (en) 2013-02-05
IS7913A (is) 2005-06-23
WO2004056823A1 (en) 2004-07-08
CO5690642A2 (es) 2006-10-31
AU2010202035B2 (en) 2012-08-30
EP1581532A1 (en) 2005-10-05
AU2003293999B2 (en) 2010-05-27
AU2010202035B9 (en) 2012-09-13
MXPA05006923A (es) 2005-08-18
HK1084384A1 (en) 2006-07-28
NO332354B1 (no) 2012-09-03
NO20053600L (no) 2005-08-22
IL169335A0 (en) 2007-07-04
CN1751042A (zh) 2006-03-22
NZ540923A (en) 2008-09-26
IS2795B (is) 2012-08-15
PT1581532E (pt) 2010-07-27
DK1581532T3 (da) 2010-08-16
KR101088848B1 (ko) 2011-12-06
CY1110676T1 (el) 2015-06-10
US7528148B2 (en) 2009-05-05
TWI354671B (en) 2011-12-21
TW201004956A (en) 2010-02-01
JP4872068B2 (ja) 2012-02-08
CN1751042B (zh) 2011-02-23
NO20053600D0 (no) 2005-07-22
PL377880A1 (pl) 2006-02-20
AU2003293999A1 (en) 2004-07-14
KR20050088214A (ko) 2005-09-02

Similar Documents

Publication Publication Date Title
PL392790A1 (pl) Związki pirazolo [3, 4-b] pirydynowe i ich zastosowanie jako inhibitorów fosfodiesterazy
IL149025A0 (en) 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo [4, 3-d] pyrimidin-7-ones as phosphodiesterase inhibitors
AU2002222293A1 (en) Pyrazolo(3,4-c)pyridines as gsk-3 inhibitors
IL181957A0 (en) Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
AU2002362895A1 (en) 5-carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
PL377661A1 (pl) Pochodne pirydyno [2,3-d] pirymidyny jako selektywne inhibitory kinaz KDR i FGFR
AP2003002857A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors.
AU2002346929A1 (en) 5-acylamino-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
IL166100A0 (en) 7,8,9-10-tetrahydro-6h-azepino,6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrroloÄ2,1-bÜ quinazolinone derivatives
AU2003284808A8 (en) The derivatives of pyridone and the use of them
IL170680A0 (en) 8 - SUBSTITUTED - 6,7,8,9 -TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
IL178899A0 (en) [3.2.0] heterocyclic compounds and methods of using the same
ZA200507192B (en) Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido [1,2-A] pyrimidin-4-one derivatives
IL163287A (en) HETEROARYL SUBSTITUTED 2 - PYRIDINYL AND 2 - PYRIMIDINYL - 6,7,8,9 - TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
IL155386A0 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
ZA200204510B (en) Imidazopyridine derivatives used as phosphodiesterase VII inhibitors.
AU2002221753A1 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
IL159540A0 (en) Heterocyclic compounds as selective bacterial dhfr inhibitors and the uses thereof
AU2003255323A8 (en) Imidazo`1,2-a pyridines
SI1534707T1 (sl) Substituirani derivati 2,4-dihidro-pirolo(3,4-b)kinolin-9-ona, uporabni kot fosfodiesterazni inhibitorji
AU2003292381A1 (en) Naphthyridine derivatives and their use as fungicides
ZA200303236B (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same.
HK1079192A (en) Pyrazolo(3,4-b)pyridine compounds, and their use as phosphodiesterase inhibitors
HK1102440A (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
ZA200206528B (en) Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors.

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)